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Angiogenesis is increasingly being recognized 
as an important prognostic factor associated 
with the progression of lymphoma and as an 
attractive  target  for  next  generation  treat-
ment modalities (Bruns et al., 2005; Koster and 
Raemaekers, 2005; Lenz et al., 2008). How-
ever, our understanding of lymphoma angio-
genesis is still in its infancy. Some recent studies 
have demonstrated that lymphoma vessels are far 
more complex than initially perceived. Apart 
from being structurally different from normal 
blood vessels, lymphoma microvessels possess 
neoplasm-specific gene alterations. For example, 
lymphoma-specific chromosomal translocations 
were detected in 15–85% of microvascular 
endothelial cells (ECs) from patients with B cell 
lymphoma (Streubel et al., 2004). Given that cy-
togenetic abnormalities confer upon lymphoma 
cells the ability to initiate malignancy and pro-
mote survival and proliferation, the presence of 
these abnormalities in lymphoma ECs might 
make lymphoma microvessels active contribu-
tors to tumor progression and dissemination, 
rather than simply conduits for nutrients and 
oxygen. Therefore, we hypothesized that lym-
phoma microvessels might possess some unique 
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Angiogenesis is increasingly recognized as an important prognosticator associated with the 
progression of lymphoma and as an attractive target for novel modalities. We report a 
previously unrecognized mechanism by which lymphoma endothelium facilitates the 
growth and dissemination of lymphoma by interacting with circulated T cells and sup-
presses the activation of CD4+ T cells. Global gene expression profiles of microdissected 
endothelium from lymphoma and reactive lymph nodes revealed that T cell immunoglobu-
lin and mucin domain–containing molecule 3 (Tim-3) was preferentially expressed in 
lymphoma-derived endothelial cells (ECs). Clinically, the level of Tim-3 in B cell lymphoma 
endothelium was closely correlated to both dissemination and poor prognosis. In vitro, 
Tim-3+ ECs modulated T cell response to lymphoma surrogate antigens by suppressing 
activation of CD4+ T lymphocytes through the activation of the interleukin-6–STAT3 
pathway, inhibiting Th1 polarization, and providing protective immunity. In a lymphoma 
mouse model, Tim-3–expressing ECs promoted the onset, growth, and dissemination of 
lymphoma by inhibiting activation of CD4+ T cells and Th1 polarization. Our findings 
strongly argue that the lymphoma endothelium is not only a vessel system but also a 
functional barrier facilitating the establishment of lymphoma immune tolerance. These 
findings highlight a novel molecular mechanism that is a potential target for enhancing 
the efficacy of tumor immunotherapy and controlling metastatic diseases.
© 2010 Huang et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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it has been extensively documented that Tim-3 is prefer-
entially expressed in differentiated Th1 cells, regulates Th1 
responses, and induces peripheral immune tolerance (Kuchroo 
et al., 2003; Sabatos et al., 2003; Sánchez-Fueyo et al., 
2003; Zhu et al., 2005). We thus selected Tim-3 for further 
study to investigate whether it is preferentially expressed in 
molecular aberrations that actively promote the progression 
of lymphoma.
One strategy to identify tumor-specific molecular abnor-
malities is to use global gene expression analysis techniques 
(Neri and Bicknell, 2005). However, a very limited number 
of studies have been done to compare the global gene expres-
sion profile associated with lymphomas versus reactive lymph 
node vessels. However, we recently developed a method for 
the analysis of global gene expression in microvessels obtained 
from primary lymph node samples (Bai et al., 2008). The micro-
vessels are isolated by laser capture microdissection (LCM) 
from lymph nodes fixed in situ and subjected to microarray 
analysis. This method has proven to be a powerful tool for 
identifying molecular details of microvessels in situ. In the 
present study, we used this technique to compare the gene 
expression profiles of microvessels from lymphomas versus 
reactive lymph nodes. Unexpectedly, we identified the ex-
pression of a transcript called T cell Ig and mucin domain–
containing molecule 3 (Tim-3), also known as hepatitis A 
virus cellular receptor 2, in microvessels of lymphomas but 
not in reactive lymph nodes. Because it has previously been 
demonstrated that Tim-3 is preferentially expressed in differ-
entiated Th1 cells and promotes immunological tolerance 
(Kuchroo et al., 2003; Sabatos et al., 2003; Sánchez-Fueyo et al., 
2003; Zhu et al., 2005), we examined expression profiles of 
Tim-3 in microvessels from lymphoma samples, which un-
derscored the potential role of endothelium-expressed Tim-3 
in the immune evasion and progression of lymphoma.
RESULTS
Transcriptional profiles of lymphoma endothelium revealed 
unexpected expression of Tim-3
To identify potential molecular aberrations in the lymphoma 
endothelium, lymph nodes from 13 patients were collected at 
the time of surgery for diagnostic purposes. Endothelium was 
isolated from the samples, and mRNA was extracted. The 
RNA samples were used for subsequent GeneChip probe 
arrays if contamination of lymphoid tissues could be excluded. 
Five lymph node samples (including two diffuse large B cell 
lymphomas [DLBCLs], one peripheral T cell lymphoma, and 
two reactive lymph nodes) were confirmed with good purity 
and were subjected to microarray analysis (Fig. 1 A). Around 
3,000 transcripts were present in each sample examined. Among 
them, several well-known vascular markers such as CD144, 
von Willebrand factor, and CD105 were detected. 13 tran-
scripts were found to be at least twofold more abundant in 
reactive lymph node–derived endothelium than in lymphoma-
derived endothelium (Fig. 1 B). 14 transcripts, on the other 
hand, were found to be at least twice as abundant in lymphoma-
derived endothelium than in reactive lymph node–derived 
endothelium (Fig. 1 B). These genes covered a wide range of 
cellular functions, such as regulation of vascular endothelial 
growth factor (VEGF) mRNA stability (Shih and Claffey, 
1999; Song et al., 2002). However, we were intrigued by the 
unexpected finding that expression of Tim-3 was more than 
twofold higher in lymphoma-derived endothelium, because 
Figure 1.  Transcriptional profiles of lymphoma endothelium.  
(A) Evaluation of purity of LCM-isolated ECs before GeneChip probe arrays. 
Five samples were used for subsequent GeneChip probe arrays. In these 
samples, the endothelial marker CD34 showed robust amplification only 
in the endothelium fraction. However, the contamination of nonendothe-
lium tissues was excluded because no T or B lymphocyte markers were 
detected. (B) Comparison of the global gene expression profiles associ-
ated with lymphomas versus reactive lymph node vessels. (left) Heat 
maps were developed with the GeneSpring hierarchical clustering algo-
rithm after eliminating all genes for which the difference in the means 
was less than the SE of the difference of means between groups. (right) 
List of genes and expressed sequence tags overexpressed in LCM-isolated 
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staining was detected in 52.38% (55 out of 105) of the lym-
phoma specimens examined. When the endothelium-expressed 
Tim-3 protein was further compared by semiquantitative 
immunoreactivity H-scoring, lymphoma endothelium dis-
played a much higher Tim-3 score than reactive lymph nodes 
(1.085 ± 0.822 vs. 0.229 ± 0.396; P < 0.001).
Next, we purified ECs from lymph nodes of lymphoma 
(n = 10) or reactive lymph nodes (n = 2), and the EC purity 
was confirmed (Fig. 2, C and D). ECs from 7 out of 10 lym-
phoma tissues stained strongly for Tim-3 protein on the cell 
membrane (Fig. 2 E). Conversely, ECs from the two reactive 
lymph nodes examined were negative for Tim-3. It was pre-
viously reported that Tim-3 mRNA is alternatively spliced to 
produce two mRNA transcripts in mice, although no such 
data are currently available in humans. The full-length transcript 
lymphoma-derived ECs, as well as what the functional sig-
nificance of Tim-3 expression might be.
Tim-3 is preferentially expressed in lymphoma-derived ECs
Given the heterogeneity of lymphomas, we first validated the 
microarray data by performing in situ hybridization on lym-
phoma cryosections (n = 10) or reactive lymph nodes (n = 10). 
Tim-3 mRNA was not detected in the endothelium in the 
majority of reactive lymph nodes; weakly stained Tim-3 mRNA 
was only detected in the endothelium of 2 out of the 10 non-
neoplastic lymph nodes. In contrast, strong staining of Tim-3 
mRNA was detected in the endothelium in 8 out of 10 lym-
phoma specimens (Fig. 2 A). Furthermore, positive endothe-
lium staining for Tim-3 protein was detected in only 10.34% 
(3 out of 29) of reactive lymph nodes (Fig. 2 B), but positive 
Figure 2.  Tim-3 is preferentially expressed on lymphoma-derived ECs. (A) In situ hybridization of cryosections of lymph nodes of lymphoma or 
reactive lymph nodes. (left) CD34-positive microvessels in lymphomas or reactive lymph nodes (brown; arrows). (right) Tim-3 transcripts (blue) were de-
tected in microvessels (arrows) in lymphomas but not in reactive lymph nodes. Bar, 20 µm. (B) Immunohistochemical staining of CD34 (left) and Tim-3 
(right) proteins. Immunoreactive Tim-3 (red arrows) was readily detectable in the endothelium (black arrows) of lymphoma but not in reactive lymph node 
endothelium. Bar, 20 µm. (C) ECs purified from lymph nodes of lymphoma or reactive lymph nodes. Isolated ECs were costained with antibodies against 
CD31 and CD105. Cells were analyzed by flow cytometry. (right) The isolated ECs were found to be >95% pure. (left) Antibody isotype control. Similar 
results were observed in three independent experiments. (D) Isolated ECs viewed by transmission electron microscopy. The ECs contained plentiful endo-
plasmic reticulum in the cytoplasm (left, arrow), and Weible-Palade bodies were observed (right, arrow). Bars: (left) 1 µm; (right) 0.2 µm. (E) ECs purified 
from lymphomas (left) and reactive lymph nodes (right) stained with an immunofluorescent anti–Tim-3 antibody and observed with a confocal laser 
scanning microscope. Tim-3 protein (green; arrowhead) is in the cell membranes of lymphoma ECs. Cell nuclei (red; arrowhead) were visualized by stain-
ing with propidium iodide. Bars, 100 µm. (F) RT-PCR of Tim-3 mRNA and sTim-3 mRNA from 10 lymphoma samples and 2 reactive lymph node samples.508 Tim-3+ endothelia assist lymphoma immune evasion | Huang et al.
stages (P = 0.043), B symptoms (i.e., fever, night sweats, and 
weight loss; P = 0.037), and higher international prognosis 
index (IPI) scores (P = 0.002). Because of the well-known 
differences in the biological and clinical behavior between 
encodes Tim-3, whereas the shorter one lacks the mucin and 
transmembrane domain and is speculated to encode soluble 
Tim-3 (sTim-3; Geng et al., 2006). The sTim-3 protein was 
previously proposed to be an inhibitory molecule in the T cell–
mediated immune response and was shown to promote can-
cer growth in tumor-bearing mice (Geng et al., 2006). To 
address whether lymph node ECs produced two isoforms of 
Tim-3, mRNA from freshly purified lymph node ECs was 
subjected  to  PCR  analysis.  Although  a  full-length  Tim-3 
transcript was detected in ECs from 8 out of 10 lymphoma 
samples, the shorter Tim-3 transcript was not detected in any 
of the 10 samples, and ECs from two reactive lymph nodes 
were negative for all Tim-3 isoforms (Fig. 2 F).
Interestingly, the unexpected expression of Tim-3 was 
also observed in microvessels of breast cancer samples. Posi-
tive endothelium staining for Tim-3 protein was detected in 
only 14.3% (2 out of 12) of mastopathia samples (Fig. S1). In 
contrast, positive staining of Tim-3 protein was detected in 
48.2% (29 out of 56) of the breast cancer specimens examined. 
When endothelium-expressed Tim-3 protein was further com-
pared by semiquantitative immunoreactivity H-scoring, breast 
cancer endothelium displayed a much higher Tim-3 score than 
mastopathia (2.438 ± 2.258 vs. 0.583 ± 1.144; P < 0.001).
Tim-3 expression in the endothelium is correlated with local 
immune profiles and adverse clinical features of lymphoma
We initially evaluated the correlation of Tim-3 expression 
with  microvessel  density  (MVD)  in  lymphoma  samples 
(Fig. 3 A). Endothelial Tim-3 protein levels were found to 
significantly correlate with the MVD of lymphoma (r = 0.446; 
P < 0.001). Next, we examined the potential correlation of 
Tim-3+ ECs (CD34+Tim-3+) with CD4+Tim-3+ T cells. The 
presence of Tim-3–expressing ECs did not appear to influ-
ence the percentage of CD4+Tim-3+ T cells observed either 
in vitro or in vivo (Fig. S2). To study the possible correlation 
of Tim-3 expression with local immune profiles in lymphoma 
sections, 12 cases of endothelial Tim-3–positive or –negative 
DLBCLs were randomly selected and compared for the den-
dritic cells expressing CD1a (Fig. 3 B) and subsets of T cells 
expressing CD4, CD8, or CD4 and CD8 (Fig. 3, C–E). 
Tim-3–positive DLBCLs had a significantly lower percent-
age of CD4+ T cells (4.41% ± 6.87% vs. 11.3% ± 7.51%; 
P = 0.03) and a lower CD4/CD8 ratio (0.23 ± 0.32 vs. 0.79 ± 
0.49; P = 0.003; Fig. 3 C) when compared with Tim-3–negative 
DLBCLs. There was no significant difference, however, in 
the  percentage  of  CD8  and  CD1a  expression  between 
Tim-3–positive and –negative DLBCLs (P > 0.05). These data 
strongly imply that endothelial Tim-3 expression in lym-
phoma might affect CD4+ but not CD8+ T cells or CD1a+ 
dendritic cells in vivo. To determine whether endothelium-
expressed  Tim-3  correlates  with  clinical  features  of  lym-
phoma, 85 cases of lymphoma with complete medical records 
were selected for analysis (Table I). No correlation was 
found between Tim-3 levels and gender, age, or histological 
origins (T or B cell lymphoma). However, high Tim-3 ex-
pression was statistically correlated with higher lymphoma 
Figure 3.  Tim-3–expressing endothelium in lymphomas correlates 
with local immune profiles. (A) Scatter plot showing Tim-3 expression 
versus MVD in 105 lymphoma samples. MVD in lymphoma sections sig-
nificantly correlated with levels of Tim-3 protein in the endothelium, as 
defined by immunoreactivity scores (r = 0.446; P < 0.001). (B) Mean (red 
lines) of CD1a+ dendritic cells. (top right) A typical image represents 
higher CD1a+ expression than the mean percentage. (bottom right) A typi-
cal image represents lower CD1a+ expression than the mean percentage. 
(C) CD4+/CD8+ cell ratio for Tim-3–negative (n = 12) and Tim-3–positive 
(n = 12) DLBCLs. Data are presented as means ± SD of at least three ex-
periments. (D) CD4+ T cell and (E) CD8+ T cell populations are presented as 
a percentage of total lymph node cells. Representative images of the lym-
phocyte population (brown; stained with antibody against CD1a+, CD4+, or 
CD8+) appear to the right of each graph. Bars, 50 µm. *, P < 0.01.JEM VOL. 207, March 15, 2010 
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to process and present antigens to T cells (Choi et al., 
2004; Danese et al., 2007). Second, lymphoma ECs harbor 
lymphoma-specific chromosomal translocations (Streubel et al., 
2004), which may serve as tumor-specific antigens. Third, a 
DNA fusion antigen created by fusing the N-terminal domain 
of fragment C of tetanus toxin (TT) with a portion of the sec-
ond domain induces strong CTL responses, and thus can be 
used as a surrogate lymphoma antigen (Rice et al., 2001; 
Padua et al., 2003).
Our first step in creating the cell model was constructing 
an adenoviral DNA vaccine, named ADV-TT (Fig. 4 A). 
ADV-TT expresses a transgene that contains the N-terminal 
domain of fragment C of TT and a portion of the second 
T and B cell lymphomas, we further analyzed the possible 
correlation between endothelium-expressed Tim-3 and the 
clinical features of T or B cell lymphoma in a separate analy-
sis. Interestingly, high Tim-3 expression was statistically cor-
related with higher lymphoma stages (P = 0.002), B symptoms 
(P = 0.014), and higher IPI scores (P = 0.001) only in B cell 
lymphoma (Table I).
Validation of a cell model for studying interactions  
between ECs and autologous T lymphocytes
To study the direct effects of Tim-3–expressing ECs on lym-
phocytes, we established a cell model based on several previ-
ous findings. First, ECs can act as semiprofessional APCs 
Table I.  Tim-3–expressing endothelium correlates with clinical features of lymphoma
Features Cases Tim-3
Scorea t p-value
Total lymphoma
Gender Male 54 0.994 ± 0.677 0.842 0.402
Female 31 1.125 ± 0.721
Age ≤40 yr 42 0.944 ± 0.71 1.289 0.201
>40 yr 43 1.137 ± 0.667
Clinical stage I+II 42 0.889 ± 0.604 2.056 0.043
III+IV 43 1.191 ± 0.745
A&B symptoms A 34 0.849 ± 0.688 2.136 0.037
B 51 1.17 ± 0.67
Histology B 48 1.026 ± 0.705 0.359 0.72
T 37 1.081 ± 0.684
IPI <2 11 0.477 ± 0.529 3.646 0.002
≥2 74 1.125 ± 0.676
B cell lymphoma
Gender Male 32 1.017 ± 0.711 0.114 0.91
Female 16 1.042 ± 0.715
Age ≤40 yr 23 0.967 ± 0.697 0.545 0.588
>40 yr 25 1.079 ± 0.722
Clinical stage I+II 28 0.755 ± 0.585 3.412 0.002
III+IV 20 1.405 ± 0.695
A&B symptoms A 27 0.814 ± 0.721 2.547 0.014
B 21 1.298 ± 0.594
IPI <2 11 0.477 ± 0.529 3.667 0.001
≥2 37 1.189 ± 0.672
T cell lymphoma
Gender Male 22 0.959 ± 0.638 1.083 0.288
Female 15 1.213 ± 0.741
Age ≤40 yr 19 0.916 ± 0.745 1.363 0.182
>40 yr 18 1.217 ± 0.593
Clinical stage I+II 14 1.157 ± 0.569 0.654 0.517
III+IV 23 1.004 ± 0.75
A&B symptoms A 7 0.986 ± 0.573 0.373 0.716
B 30 1.08 ± 0.714
IPI <2 0
≥2 37 1.062 ± 0.683
aExpression score (mean ± SE). The expression score represents the expression level of Tim-3 protein in endothelium as calculated by the immunoreactivity scoring system. 
Corresponding t values and p-values are displayed for each cross tabulation.510 Tim-3+ endothelia assist lymphoma immune evasion | Huang et al.
activation of lymphocytes appeared to be, for the most part, 
TT dependent, because ADV-GFP triggered a much lower 
level of lymphocyte proliferation (Fig. 4 C).
To further address whether the antigen-presenting func-
tion of UVECs to CD4+ T cells was specific, MHC class II–
positive cells (i.e., the human bronchial epithelial cell line 
BEAS) were used as a control. After pretreatment with IFN-, 
MHC class II molecules were detected on BEAS. Although 
ADV-TT–infected UVECs stimulated autologous lympho-
cytes to proliferate (4.75 ± 0.58), ADV-TT–infected BEAS 
was not able to induce HLA-A2–matched lymphocyte pro-
liferation (1.61 ± 0.33; P < 0.01; Fig. 4 D). To rule out the 
possibility that differential lymphocyte proliferation was caused 
by the influence of ADV-TT on UVECs, we analyzed the 
effect of ADV-TT infection on UVEC proliferation and sur-
vival.  ADV-TT  infection  did  not  lead  to  an  increase  in 
UVEC cell numbers when compared with the UVEC/PBS 
control (Fig. 4 E). At a multiplicity of infection (MOI) of 250, 
domain. To mimic lymphoma ECs, human umbilical vein ECs 
(UVECs) were infected with ADV-TT to express the trans-
gene (Fig. 4 A). The infected UVECs were then incubated 
with lymphocytes from the same donor (autologous lympho-
cytes) in the presence or absence of Tim-3 expression. Next, 
we checked whether MHC and co-stimulatory molecules 
were expressed in the UVECs (Fig. 4 B), and they were 
found to constitutively express MHC class I and CD58 mol-
ecules. After pretreatment with IFN-, MHC class II (but 
not CD86) molecules were detected on UVECs. These data 
demonstrated that, after pretreatment with IFN-, UVECs 
expressed the MHC and co-stimulatory molecules necessary 
for presenting antigens to both CD4+ and CD8+ T cells. On 
the other hand, infection of IFN-–pretreated UVECs with 
ADV–Tim-3 did not alter the expression of the MHC and 
co-stimulatory molecules (Fig. 4 B). When co-cultured, ADV-
TT–infected UVECs stimulated autologous lymphocytes 
to proliferate in an ADV-TT dose-dependent fashion. The 
Figure 4.  Validation of an in vitro cell model for studying interactions between ECs and autologous T lymphocytes. (A, top) Schematic of 
the ADV-TT construct. (bottom) Transcripts of TT in ADV-TT–infected UVECs were detected by RT-PCR. ADV-GFP and PBS were included as negative 
controls. (B) Expression of MHC class I, MHC class II, CD86, or CD58 in freshly isolated UVECs treated with PBS (black), IFN- (green), or IFN- + ADV–
Tim-3 (red). (C) UVECs were infected with ADV-TT or ADV-GFP and incubated with CFSE-labeled autologous lymphocytes. The proliferation of lympho-
cytes was measured by FACS. (right) CFSE profiles of lymphocytes treated with ADV-GFP or ADV-TT. Data are represented as means ± SD of triplicates. 
(D) BEAS and UVECs were infected with ADV-TT at an MOI of 250 and incubated with CFSE-labeled autologous lymphocytes. The proliferation of lym-
phocytes was measured by FACS. (right) CFSE profiles of lymphocytes treated with ADV-TT. Data are represented as means ± SD of triplicates. (E) Cell 
proliferation of UVECs infected with various titers of ADV-TT. Infection of ADV-TT did not lead to an increase in UVEC cell numbers compared with 
infection with ADV-GFP or at any of the MOIs examined. Data are represented as means ± SD of triplicates. Similar results were observed in four  
(B) or three (C–E) independent experiments.JEM VOL. 207, March 15, 2010 
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the proliferation of CD4+ and CD8+ T cells was signifi-
cantly inhibited by ADV–Tim-3. Importantly, the CD4+/ 
CD28high T lymphocytes decreased significantly after exposure 
to ADV–Tim-3. On the other hand, the CD8+/CD28high and 
T reg (CD4+/CD25+/CD127low) cell populations (Tiemessen 
et al., 2007) were not altered by ADV–Tim-3 (Fig. 5 G). 
These data indicated that the immune target cells of Tim-3 
were CD4+, CD4+/CD28high rather than the CD8+/CD28high 
and T reg cell subsets, which is in agreement with our clinical 
data (Fig. 3, D and E).
We further identified that ADV–Tim-3 suppressed acti-
vation of CD4+/IFN-+ but not CD8+/IFN-+ (Fig. 5 H). 
To further confirm this finding, UVEC/T cell co-cultured 
supernatants were analyzed for the production of Th1/Th2 
cytokines. Despite the fact that the production of IL-4 and 
IL-2 was not influenced by Tim-3, ADV–Tim-3 appeared to 
promote production of Th2 cytokines (IL-10; ADV–Tim-3 
vs. ADV-GFP, P = 0.005) and inhibit the production of Th1 
cytokines (IFN- and TNF; ADV–Tim-3 vs. ADV-GFP; 
Fig. 5 I). To further test whether Tim-3–expressing ECs de-
rived from primary lymphoma tissues suppressed antigen-
induced  activation  of  CD4+  T  cells,  a  15-mer  peptide 
mapping to the 167–181 region of VEGFR-2 (which has 
been shown to induce a specific CD4+ T cell response in 
several HLA-DR alleles [Sun et al., 2008], including DR4 
and DR7) was used. ECs were purified from fresh lymph node 
tissues of lymphoma patients with HLA-DRB1*1501 (n = 2) 
and HLA-DRB1*0701 (n = 1), and the purity of the ECs 
was confirmed (Fig. S3 A). Notably, all of the ECs derived 
from the three lymphoma patients had negative expression of 
Tim-3 (Fig. S3 A). It should be emphasized that the ECs in 
this experiment were different from those used in other parts 
of the study. To obtain enough ECs for the present experi-
ment, lymphoma ECs were isolated and amplified through a 
culture procedure taking >15 d. It is possible that ECs clonally 
related to lymphoma are not maintained or expanded under in 
vitro conditions, which is in agreement with our previous ob-
servations (Wu et al., 2009). Although the VEGFR-2 peptide–
loaded ECs activated the autologous CD4+ and CD8+ T cell 
response, the CD4+ activation was abolished by the expres-
sion of Tim-3 (Table S2). On the other hand, the CD8+ 
was not altered by ADV–Tim-3, which led to a significantly 
decreased CD4/CD8 ratio (1.16 ± 0.22 vs. 2.37 ± 0.29;   
P = 0.004; Fig. S3 B).
To explore the possible mechanisms underlying the neg-
ative effects of Tim-3–expressing ECs on the activation of 
lymphocytes, UVECs infected with ADV-TT and ADV–
Tim-3 were fixed with paraformaldehyde, incubated with 
CFSE-labeled lymphocytes, and subjected to proliferation 
assays. Although ADV-TT–stimulated lymphocyte prolifer-
ation was suppressed by Tim-3–expressing ECs, the suppres-
sion was partially reversed providing that Tim-3–expressing 
ECs were prefixed with paraformaldehyde (Fig. 6 A). These 
results imply that both the direct cell contact of ECs with 
lymphocytes and other factors may play roles in the suppres-
sion of lymphocyte activation. Next, we examined the effects 
ADV-TT–infected UVECs significantly activated T lympho-
cytes with a minor cell death response (unpublished data); thus, 
this concentration was used in the following experiments.
In the first experiment with our cell model, we analyzed 
the  proliferation  of  CD4+  and  CD8+  T  cells  induced  by 
ADV-TT–infected UVECs (Table S1). Upon exposure to 
ADV-TT–infected UVECs, the CD4+ cell number increased 
to 13.16 ± 1.59 × 105 cells/well, much higher than that of the 
PBS (8.95 ± 1.35 × 105 cells/well) or ADV-GFP–infected 
(9.14 ± 1.88 × 105 cells/well) UVEC control groups (P < 
0.05). In the same experiment, the CD8+ cell number also in-
creased moderately in response to ADV-TT–infected UVECs 
(0.83 ± 0.15× 105 cells/well) when compared with the PBS 
(0.61 ± 0.09 × 105 cells/well) and ADV-GFP–infected (0.69 ± 
0.12 × 105 cells/well) UVEC control groups (P < 0.05). 
These data demonstrated that surrogate antigen TT-expressed 
UVECs activated both CD4+ and CD8+ T lymphocytes, and 
thus can be used as a cell model to investigate the direct effects 
of Tim-3–expressing ECs on T lymphocytes.
Tim-3–expressing ECs suppressed antigen-induced activation 
of CD4+ T cells through activation of the IL-6–STAT3 
pathway and provided protective immunity
UVECs  were  infected  with  ADV–Tim-3  to  ectopically 
express Tim-3 (Fig. 5 A). As expected, the lymphocyte pro-
liferation in response to ADV-TT–infected UVECs was sig-
nificantly suppressed by ADV–Tim-3 in a dose-dependent 
fashion (Fig. 5, B and C). To explore whether ADV-TT led 
to expansion of a specific T cell clone, we used Biomed-2 
multiplex TCR PCR to analyze the T cell repertoire (Fig. 5 D; 
van Dongen et al., 2003; van Krieken et al., 2007). PCR 
products  amplified  from  lymphocytes  co-cultured  with 
ADV-TT–infected UVECs showed a specific clonal expansion 
of TCR, as defined by an enhanced 220-bp single PCR 
band. This TCR clonal expansion against ADV-TT was 
completely inhibited by ADV–Tim-3 (Fig. 5 D), implying 
that the antigen-specific T cell response against ADV-TT 
was abolished by Tim-3. To address whether the responding 
subset of T cells were T cells, we repeated the Biomed-2 
multiplex TCR PCR experiments using purified CD4+ and 
CD8+ cells co-cultured with ADV-TT–infected UVECs. A 
specific clonal expansion was detected both in CD4+ and 
CD8+ T cells, indicating that the responding clonal expan-
sion to ADV-TT is via CD4+/CD8+ T cells rather than T 
cells. Again, the CD4+ T cell clonal expansion was abolished 
by Tim-3–expressing ECs (Fig. 5 E).
We then asked whether the suppression of T cell prolif-
eration by Tim-3 resulted in protective immunity (Fig. 5 F). 
Although autologous T lymphocytes activated by ADV-TT–
infected dendritic cells effectively killed ADV-TT–infected 
UVECs, the killing efficacy was significantly inhibited by 
ADV–Tim-3 but not by ADV-GFP. To identify which T cell 
subsets were influenced by Tim-3, we observed the various 
T cell subsets in the presence or absence of ADV–Tim-3 
(Table S1). Autologous T lymphocytes responded to ADV-
TT–infected UVECs with significant proliferation. However, 512 Tim-3+ endothelia assist lymphoma immune evasion | Huang et al.
Figure 5.  Expression of Tim-3 in UVECs abolished the activation of CD4+ T cells and provided protective immunity. (A) Expression of Tim-3 was 
determined by Western blotting in UVECs infected with ADV–Tim-3 or treated with PBS. (B) UVECs infected with various adenoviral mutants were incubated 
with CFSE-labeled lymphocytes and subjected to proliferation analysis. ADV–Tim-3 but not ADV-GFP inhibited the proliferation of lymphocytes. Data are rep-
resented as means ± SD of triplicates. (C) Typical CFSE profiles of lymphocytes with different treatments. (D) Biomed-2 multiplex TCR PCR to analyze the T cell 
repertoire after various treatments. UVECs infected with ADV-TT were incubated with lymphocytes. Multiplex PCR was used to amplify six TCR subfamily genes 
from activated lymphocytes. (left) A positive clonal TCR rearrangement against ADV-TT (arrows). (right) The positive clonal TCR rearrangement against ADV-
TT (arrow) was inhibited by ADV–Tim-3. (E) Biomed-2 multiplex TCR PCR to analyze the T cell repertoire after various treatments. UVECs infected with ADV-TT 
were incubated with isolated CD4+ or CD8+ T cells. Multiplex PCR was used to amplify six TCR subfamily genes from activated lymphocytes. The positive clonal 
TCR rearrangement against ADV-TT was inhibited by ADV–Tim-3 in CD4+ T cells (white arrows) but not in CD8+ T cells (red arrows). (F) Lymphocytes were 
incubated with ADV-TT–infected dendritic cells. The resulting CTLs were added to ADV-TT–infected UVECs in the presence or absence of ADV–Tim-3. The cul-
ture supernatant was then determined by an LDH release assay for specific lysis. Data are represented as means ± SD of triplicates. (G) UVECs were infected 
with varied viral mutants and incubated with autologous lymphocytes. Lymphocytes were analyzed for T cell subpopulations. Data are represented as means ± 
SD of triplicates. (H) Lymphocytes were treated as described in G and analyzed for CD4+/IFN-+ and CD8+/IFN-+ populations. Data are represented as means 
± SD of triplicates. (I) UVEC/T cell culture supernatants were measured for production of the Th1/Th2 cytokines IFN-, TNF, IL-10, IL-4, and IL-2. Data are repre-
sented as means ± SD of triplicates. Similar results were observed in three (A, B, and F–I) or four (D and E) independent experiments. *, P < 0.01.JEM VOL. 207, March 15, 2010 
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ADV-GFP or ADV–Tim-3 before injection into the same 
site for lymphoma inoculation. The presence of adenoviral 
mutant–infected ECs in vivo was confirmed by tracking 
ADV-GFP. 1 d after the EC injection, the engrafted ECs 
scattered within the tumor (Fig. S4 F). 2 d after the injec-
tion, some microvessels formed by the engrafted ECs were 
detected (Fig. S4 G). Importantly, Tim-3–expressing ECs sig-
nificantly accelerated the onset of lymphoma when compared 
with ADV-GFP– or PBS-treated ECs (Fig. 7, A and B). More 
importantly,  all  mice  that  received  ADV–Tim-3–infected 
ECs displayed evidence of dissemination within 26 d of in-
oculation. In the same experiments, only 25% of the mice in 
the PBS control group and 12.5% of the mice in the ADV-
GFP group were found to have disseminated tumors. The 
CD4+ T lymphocytes in peripheral blood collected from 
lymphoma-bearing mice from all three groups were analyzed 
26 d after inoculation with lymphoma cells (Fig. 7 C). The 
percentage of CD4+ T lymphocytes from PBS- or ADV-
GFP–treated  mice  was  significantly  higher  than  that  of 
ADV–Tim-3–treated mice (ADV–Tim-3 vs. PBS group, 
P = 0.004; ADV–Tim-3 vs. ADV-GFP group, P = 0.02). 
The  CD4+  lymphocytes  in  the  spleens  of  ADV–Tim-3–
treated mice also showed a decrease when compared with 
those from control mice treated with PBS or ADV-GFP 
(ADV–Tim-3 vs. PBS group, P = 0.017; ADV–Tim-3 vs. 
ADV-GFP group, P = 0.033; Fig. 7 D). In the same experi-
ment, CD8+ lymphocytes exhibited a decreasing trend in the 
ADV–Tim-3–treated group, but no statistically significant 
difference was observed. We next analyzed the serum, spleen 
cells, and lymphoma tissue for basal levels of Th1 (IFN-, 
TNF, and IL-2) and Th2 (IL-5 and IL-4) cytokines. In the 
ADV–Tim-3 group, the basal levels of Th1 cytokines (TNF 
in serum, TNF and IFN- in spleen cells and lymphoma 
tissue) were significantly lower than those in the ADV-GFP or 
PBS group (Table S3). We further analyzed the lymphocytes 
that infiltrated the tumor and found that the CD4+ T cell 
subset  was  significantly  lower  in  the  ADV–Tim-3  group 
(ADV–Tim-3 vs. PBS group, P = 0.025; ADV–Tim-3 vs. 
ADV-GFP group, P = 0.01; Fig. 7 E), although no signifi-
cant change was observed in CD8+ T cell numbers (Fig. 7 F). 
To test whether Tim-3–expressing ECs facilitated the devel-
opment of lymphoma via inhibition of CD4+ T cells, A20 
mice B cell lymphoma models were used. Anti-CD4 block-
ing antibody significantly accelerated the onset of lymphoma 
compared with the PBS-treated group (Fig. S5 A). More 
importantly, Tim-3–expressing ECs did not further accelerate 
the onset of lymphoma in mice models pretreated with anti-
CD4 blocking antibody, implying that the immunosuppres-
sive effects of Tim-3–expressing ECs act through inhibition 
of CD4+ T cells. To further support this notion, we exam-
ined whether injection of Tim-3–expressing ECs inhibited 
the activation of T cell responses against the delayed type 
hypersensitivity (DTH) response. Again, Tim-3–expressing 
ECs significantly diminished the DTH response as defined 
by ear swelling (P < 0.05; Fig. S5, B–D) and spleen edema 
reactions (P < 0.05; Fig. S5 E).
of Tim-3 expression on the production of various cytokines 
in ECs. Strikingly, although the production of most of cyto-
kines  in  ECs  remained  unaffected,  Tim-3  expression  in-
creased the EC-derived production of IL-6 by almost 10-fold 
(P < 0.01; Fig. 6 B). To address the functional significance 
of increased IL-6 production in ECs, we initially examined 
the impact of recombinant IL-6 on the phosphorylation of 
the  STAT3  protein  in  UVECs  and  ADV-TT–stimulated 
lymphocyte proliferation. We found that addition of IL-6 
significantly increased the level of phosphorylated STAT3 
(p-STAT3) in UVECs (Fig. 6 C). Furthermore, ADV-TT–
stimulated lymphocyte proliferation was substantially inhib-
ited by IL-6 (Fig. 6 D). To further confirm the critical role 
of p-STAT3 in Tim-3+ EC–mediating immunosuppression, 
we examined the level of p-STAT3 in Tim-3–expressing 
UVECs. As expected, STAT3 phosphorylation was strik-
ingly enhanced in Tim-3–expressing UVECs (Fig. 6 E). In-
terestingly, S3I201, a specific STAT3 inhibitor, inhibited the 
phosphorylation of STAT3 and consequently abolished the 
immunosuppressive effects of Tim-3–expressing ECs (P < 
0.05; Fig. 6 F). Obviously, the effect of S3I201 is not caused 
by nonspecific effects, because S3I201 at a dose of 50 µM did 
not increase apoptosis of UVECs or alter the expression of 
MHC and co-stimulatory molecules in UVECs (unpublished 
data). To explore the effects of engagement of Tim-3 by its 
ligands  (e.g.,  galectin-9),  Tim-3–expressing  UVECs  were 
analyzed for production of IL-6 in the presence of recombi-
nant galectin-9 protein. Strikingly, galectin-9 substantially 
enhanced the secretion of IL-6 in Tim-3–expressing ECs 
(Fig. 6 G). To explore the interaction between Tim-3 and T 
lymphocytes, we incubated autologous CD4+ or CD8+ lym-
phocytes with a DsRed recombinant Tim-3 fusion protein 
to identify the target T subsets. Our results revealed that CD4+ 
(7.12 ± 0.55%) but not CD8+ (0.25 ± 0.18%) T cells were 
the target cells bound by DsRed Tim-3 (Fig. 6 H). Consistent 
with our data observed with recombinant galectin-9, Tim-3–
expressing ECs in the presence of paraformaldehyde-fixed 
CD4+ T cells increased IL-6 secretion by almost 30-fold and 
substantially  promoted  the  phosphorylation  of  STAT3  in 
UVECs (P < 0.01; Fig. 6, I and J). These data argue for a 
critical role of the interaction between CD4+ T cells and 
Tim-3–expressing ECs in suppressing lymphocyte activation 
through activation of the IL-6–STAT3 pathway. To support 
this notion, our protective immunity assay showed that the 
immunoprotection mediated by Tim-3 was considerably 
diminished by an anti-CD4 antibody (Fig. 6 K).
Tim-3–expressing ECs facilitate the progression  
of lymphoma in vivo
We next determined whether Tim-3–expressing ECs facili-
tated the progression of lymphoma in a mouse model, and the 
characterization of lymphoma in TA2 mice was confirmed 
(Fig. S4, A–E). The TA2 mice lymphoma was a B-lineage 
lymphoma. To observe the effects of Tim-3–expressing ECs 
on the growth of lymphoma in vivo, ECs were isolated from 
the bone marrow of healthy TA2 mice and infected with 514 Tim-3+ endothelia assist lymphoma immune evasion | Huang et al.
Figure 6.  Mechanisms underlying the negative impact of Tim-3–expressing ECs on the activation of lymphocytes. (A) UVECs infected with 
ADV-TT and ADV–Tim-3 were fixed with 2% paraformaldehyde, incubated with CFSE-labeled lymphocytes, and subjected to proliferation analysis. (left) 
Although ADV-TT–stimulated lymphocyte proliferation was suppressed by Tim-3–expressing ECs, the suppression was partially reversed if Tim-3–expressing 
ECs were fixed by paraformaldehyde. (right) Typical CFSE profiles of lymphocytes in response to different treatments. PF, UVECs fixed with 2% 
paraformaldehyde. (B) The supernatants of UVECs infected with various adenoviral mutants were determined for production of the Th1/Th2 cytokines 
IL-2 (purple), IL-4 (yellow), IL-6 (red), IL-10 (blue), TNF (orange), and IFN- (green). Data are represented as means ± SD of triplicates. (right) Typical 
results of CBA analysis determined by flow cytometry. (C) UVECs were treated with 50 ng/ml IL-6 or PBS (negative control) for 48 h and analyzed for 
levels of p-STAT3. (D) UVECs were treated as described in C and subjected to lymphocyte proliferation analysis. (E) UVECs were treated as depicted and 
examined for levels of p-STAT3 protein. S3I201, UVECs treated with 50 µM S3I201 for 48 h. (F) UVECs were treated as described in E, and lymphocyte 
proliferation index were determined. (G) 300 µl of supernatants containing recombinant galectin-9 was mixed with 200 µl of culture medium, added 
into UVECs infected with ADV-GFP or ADV–Tim-3, and cultured for 48 h before IL-6 assays. Supernatants from empty vector-transfected CHO cells were 
used as a control. (H) 200 µl of CHO cell supernatants (from cells transfected with pTim-3–RED [right] or pDsRed-Express-1 [left]) was added to 5 × 105 
autologous T lymphocytes. After incubation for 3 h, the cells were subjected to flow cytometry analysis for the percentage of RED-positive cells. Con, 
addition of supernatant of the CHO cells transfected with pDsRed-Express-1 (left). (I) Tim-3–expressing UVECs were incubated with paraformaldehyde-fixed JEM VOL. 207, March 15, 2010 
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supports the notion that ECs act as semiprofessional APCs and 
present antigens to T cells as an immune surveillance mecha-
nism (Choi et al., 2004; Danese et al., 2007). Although pro-
fessional APCs induce antitumoral immunity, in our hands, 
lymphoma-derived ECs expressed lymphoma antigens and 
then induced immune tolerance to the antigens by expressing 
Tim-3. It appears that Tim-3–expressing ECs inhibit the re-
sponse of lymphocytes to antigens through the activation of 
the  STAT3  pathway.  Tim-3  expression  considerably  en-
hanced EC-secreted IL-6, gave rise to an elevated level of 
p-STAT3,  and  suppressed  the  activation  of  lymphocytes. 
Furthermore, the cascade of IL-6 production and consequent 
STAT3 phosphorylation was substantially enhanced by an in-
teraction of Tim-3–expressing ECs with CD4+ cells, the tar-
get T subset for Tim-3. Currently, there are several important 
questions that remain to be addressed. For example, what is the 
exact subpopulation of CD4+ T cells bound by EC-associated 
Tim-3? What is the exact receptor on the CD4+ cell surface 
for binding Tim-3–expressing ECs? What are the functional 
fates of CD4+ T cells upon binding to Tim-3–expressing 
ECs? The answers to these questions will clarify the question 
of why CD8+ T cells were less affected by Tim-3–expressing 
ECs and extend our understanding of the mechanisms un-
derlying tumor evasion and improve the targeting of future 
therapies. Nevertheless, our results suggest that angiogen-
esis is far more crucial to lymphoma progression than was 
previously thought. Not only does the lymphoma endothe-
lium facilitate the successful dissemination and progression 
of lymphoma by supplying oxygen and metabolites and   
allowing lymphoma cells to access the vasculature and spread 
to distal sites, but it also switches off immune surveillance. 
Thus, acquisition of increased potential for lymphoma dis-
semination could be endowed and maintained by lymphoma 
ECs by themselves.
Our findings have important clinical implications. Lym-
phoma is considered to be a potentially curable malignancy; 
however, a large number of cases of advanced lymphoma 
eventually become refractory or relapse after initial treatment 
because of the persistence of residual disease. These patients 
are considered incurable using the available treatment options, 
and there is an urgent need for novel treatment modalities. 
Active immunotherapy is a promising approach and is being 
investigated as a next generation strategy for lymphoma treat-
ment. Current immune therapy includes several approaches, such   
as idiotype vaccines, DNA vaccines, and engineering antigen-
specific T cells (Maloney, 2005). Whatever the active immuno-
therapy approach used, the penetration of activated T cells 
through the lymphoma endothelium is one of the most im-
portant factors for determining antitumoral efficacy. The 
DISCUSSION
Although Tim-3–expressing CD4+ T cells have previously 
been shown to interact with the Tim-3 ligand, inhibit effec-
tor Th1 cells during the normal immune response, and induce 
peripheral tolerance (Kuchroo et al., 2003; Sabatos et al., 2003; 
Sánchez-Fueyo et al., 2003; Zhu et al., 2005), their role in 
inducing tumor immune evasion has not been recognized. 
The present findings highlight a novel molecular mechanism 
by which expression of Tim-3 in the lymphoma endothe-
lium causes active interaction with circulating T cells, sup-
presses the activation of CD4+ T cells, and contributes to the 
establishment of lymphoma immune tolerance. Because the 
essential role of CD4+ T cells in antitumoral immunity is well 
established, suppression of the activation of the CD4+ T cell 
response by the tumoral endothelium is intriguing. The pres-
ent findings strongly support a critical role for endothelial tis-
sue in lymphoma progression, and suggest that the lymphoma 
endothelium is not only a vessel system that supplies oxygen 
and nutrients to tumor sites but also a functional barrier that 
assists the tumor in immune evasion (Gunsilius et al., 2000; 
Fidler and Ellis, 2004; Rigolin et al., 2006; Pezzolo et al., 2007; 
Gao et al., 2008). Recently, an independent group has shown 
that survival of DLBCLs after treatment was substantially in-
fluenced by the gene expression signatures of certain types of 
tumor microenvironments. DLBCLs with the signature that 
reflected increased lymphoma blood vessel density were as-
sociated with adverse clinical outcome (Lenz et al., 2008). 
These findings are very consistent with our data and strongly 
support our conclusions.
Previous well-known mechanisms of immune evasion by 
tumors involve several factors, such as tumor cells, T reg cells, 
dendritic cells, and mesenchymal stem cells (Kim et al., 2006; 
Karnoub et al., 2007). The findings presented here should 
extend our understanding of tumor immune evasion by un-
derscoring the critical role of lymphoma-derived ECs. That 
the lymphoma endothelium works as an immune barrier that 
actively suppresses antitumoral immunity is a novel and im-
portant concept for the following reasons. First, human en-
dothelial tissue is composed of 1–6 × 1013 ECs lining a total 
surface area of 4,000–7,000 m2, and they form an enormous 
interface between circulating immune cells and underlying 
tissues (Danese et al., 2007). Second, a significant proportion 
of lymphoma-derived ECs have lymphoma-specific chromo-
somal translocations, which give rise to lymphoma-specific 
antigens (Streubel et al., 2004). In addition, a dominant pro-
portion of circulating ECs in bone marrow or peripheral 
blood also harbors tumor-specific chromosomal translocations 
in some malignancies (Wu et al., 2009), and can potentially 
interact with the immune system. Third, mounting evidence 
CD4+ or CD8+ T cells and the levels of p-STAT3 were determined. (J) Tim-3–expressing UVECs were treated as described in I and the production of IL-6 
was determined. (K) Lymphocytes were incubated with ADV-TT–infected dendritic cells. The resulting CTLs were added to ADV-TT–infected UVECs in the 
presence or absence of ADV–Tim-3. Anti-CD4 blocking antibody was added into the co-cultured system at a final concentration of 8 µg/ml. The culture 
supernatant was then examined by an LDH release assay for specific lysis. Data are represented as means ± SD of triplicates. Similar results were ob-
served in four (A and C–F) or three (B and G–K) independent experiments. *, P < 0.05.
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Figure 7.  Tim-3–expressing ECs impair T cell antitumor immunity and facilitate tumor growth in vivo. TA2 mice were inoculated into the 
inguinal groove muscle with 5 × 105 lymphoma cells. ECs were isolated and purified from the bone marrow of healthy TA2 mice and infected with ADV–
Tim-3, ADV-GFP, or PBS. Each group included eight model mice. 5 × 104 ECs were injected into the same site for tumor inoculation on days 3, 6, and 9 
after tumor implantation. (A) Cumulative probability of tumor onset was determined by the appearance of neoplasms into the inguinal groove muscle. In 
PBS- or Adv-GFP–treated EC groups, lymphoma formation at the inoculation sites took an average of 18.5 ± 3.4 d or 18.8 ± 3.6 d, respectively, whereas 
ADV–Tim-3–infected ECs significantly shortened the formation time of lymphomas at primary sites to 14.3 ± 1.2 d (ADV–Tim-3 versus PBS group, P = 
0.01; ADV–Tim-3 versus ADV-GFP group, P = 0.01). (B) Tumor volume was monitored. (C) Peripheral blood cells and (D) spleen cells from TA2 mice were 
stained with an FITC-conjugated mAb to mouse CD4 and CD8 and analyzed by flow cytometry. (top) Representative data of flow cytometry analysis. 
(bottom) Data in columns are representative of four experiments and represented as means ± SD. (E) CD4+ and (F) CD8+ T cell populations as percentages 
of total tumor cells are shown. Horizontal bars represent means. Representative immunofluorescence images of infiltrating lymphocyte populations 
(green; arrowheads) are shown against the background of tumor cells (red). Bars, 20 µm. *, P < 0.05; **, P < 0.01.
lymphoma  endothelium–mediated  immune  suppression  of 
the CD4+ T cell response further proves that it is necessary to 
therapeutically target immune suppression mechanisms in ad-
dition to using adoptive immune therapy. Finally, there is 
mounting evidence for the critical role of the tumor micro-
environment in tumor dissemination (Karnoub et al., 2007; 
Steeg and Theodorescu, 2008). If the increased metastatic po-
tential of tumor cells can be initiated and maintained by the JEM VOL. 207, March 15, 2010 
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data from the GeneChips. This software allowed us to calculate the signal 
and determine whether an expressed transcript was present or absent. Micro-
array data have been deposited in the Gene Expression Omnibus under ac-
cession no. GSE19882.
In situ hybridization. In situ hybridization was performed on lymph node 
tissue cryosections with 1 µg/ml of biotinylated oligonucleotide probe com-
plementary  to  the  Tim-3  coding  region  (5-TGCTGCTACTACTTA-
CAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTC-3). Negative 
controls were similarly processed with the probe omitted.
Immunohistochemistry. Paraffin-embedded tissue sections were dewaxed 
in xylene and subjected to immunohistochemical analysis as previously de-
scribed (Geng et al., 2006). An anti-CD34 mouse monoclonal antibody 
(Changdao Biotech Co.), anti–Tim-3 goat polyclonal antibody (Santa Cruz 
Biotechnology, Inc.), and biotinylated secondary antibody were used in the 
present study. For semiquantitative evaluation, an immunoreactivity-scoring 
(IRS) system was applied. Intensity of staining was designated as either non-
existent (0), weak (1), moderate (2), or strong (3). The percentage of positive 
cells was termed as the expression score. The IRS was calculated by multiply-
ing the expression score with the intensity score and ranged from 0–3. Sam-
ples with IRS scores of 0–1 point were considered negative for Tim-3 
expression; otherwise, the samples were designated as positive. These data 
were analyzed along a continuum, and the objective was to use this semiquan-
titative method to assess differences between various experimental groups. 
For analysis of MVD, the microvessels were labeled with anti-CD34 anti-
body and counted under a low-power field (200×). MVD counts were de-
fined as the number of microvessels per 0.2 mm2. Criteria for positive staining 
and microvessel counting followed the method described by Weidner (1995). 
The mean MVD values were calculated in five areas of the tumors. For char-
acterization of lymphoma immune profiles, 24 cases of DLBCL were divided 
into two groups according to positive (n = 12) or negative (n = 12) expres-
sion of Tim-3 in the microvascular endothelium. Primary antibodies in-
cluded anti-CD4, anti-CD8, and anti-CD1a (all from Dako). A horseradish 
peroxidase kit (EnVision+ System; Dako) was used to detect immune reac-
tivity. The slides were read and scored by two pathologists who blinded each 
other to prevent observer bias. Data resulting from cell counts and area rep-
resent an average of five high-power fields (Coventry and Morton, 2003). 
Each data point represents the mean of the results from two pathologists.
Preparation of cells. Purification of ECs from fresh lymph nodes were per-
formed as described previously (Streubel et al., 2004). The purified ECs were 
then processed for other experiments. For isolation of UVECs, umbilical 
cords provided by healthy human volunteers were processed as described 
previously (Cooke et al., 1993) and cultured in M199 supplemented with 20% 
FCS, 10 ng/ml of epithelial growth factor, 35 µg/ml gentamycin, 1 µg/ml 
hydrocortisone, and 2.5 µg/ml amphotericin B. UVECs were digested using 
0.25% trypsin and 1 mM EDTA (Invitrogen), seeded onto uncoated 24-well 
plates, and cultured for 4 d. Each experiment used first-passage cells from one 
umbilical cord. Autologous T lymphocytes were obtained from heparinized 
cord blood of the same volunteers according to a standard protocol using 
Ficoll-Hypaque (GE Healthcare) density-gradient centrifugation. To study the 
interaction of UVECs with autologous T cells, UVECs were infected with 
various adenoviral mutants at different titers. Autologous T lymphocytes were 
then mixed with the UVECs at a ratio of 10:1 in the presence of 50 U/ml 
IL-2 (Sigma-Aldrich) for the first round of vaccination. On day 4, T lympho-
cytes were transferred into a new well with infected UVECs for the second 
round of vaccination, lasting for another 3 d. Cord blood–derived dendritic 
cells were generated as described previously (Wong et al., 2005).
Adenoviral mutants. All adenoviral mutants used in the present study 
were constructed in our laboratory following standard protocols described 
previously (Zhou et al., 2005). ADV-GFP contains a GFP gene under the 
control of a Rous sarcoma virus long terminal repeat promoter in the region 
of the excised E1 adenoviral genes. All other replication-deficient adenovirus 
tumor-derived endothelium, targeting lymphoma angiogene-
sis is expected to curtail and possibly even reverse lymphoma 
dissemination. Further evaluating the contribution of the 
endothelium in immune evasion of lymphoma and other solid 
tumors will provide novel strategies for controlling tumor dis-
semination by targeting tumor-derived ECs.
MATERIALS AND METHODS
Tissue samples. Lymph node samples were obtained at the time of surgery 
for diagnostic purposes according to a protocol approved by the Institutional 
Review Board for Human Research at Tongji Hospital. Lymph nodes were 
collected from 134 patients: 30 cases with DLBCL, 22 cases with peripheral 
T cell lymphoma, 53 cases with other types of lymphoma, and 29 cases with 
reactive lymph nodes. No chemotherapy or radiotherapy was performed 
before collection of the tissue samples. All samples were sectioned for both 
immunohistochemical and hematoxylin and eosin staining for histological 
diagnosis by pathologists according to the classification of the World Health 
Organization. For GeneChip probe arrays and validation of microarray data, 
a higher quality tissue free of RNA degradation was needed. Samples for this 
purpose were therefore collected separately and processed according to our 
previous description (Bai et al., 2008). An additional 53 lymph node samples 
were obtained, of which 13 were used for microarray analysis, 20 were used 
for in situ hybridization, and 12 were used for purification of ECs for cell 
culture. Eight lymph nodes were not used because of the poor sample quality 
or being diagnosed as metastatic cancer.
Oligonucleotide microarray for endothelium isolated from lymph 
node tissues. Endothelium was isolated from primary lymph node tissues 
and subjected to RNA microarray analysis for global gene expression profiles 
according to our previously published protocol (Neri and Bicknell, 2005). In 
brief, lymph nodes were obtained within 15 min after removal from the pa-
tients. Under RNase-free conditions, lymph nodes were retrieved and im-
mediately immersed in prechilled fixatives. The sections of the samples were 
evaluated by pathologists for histological diagnosis and subjected to immuno-
histochemical staining with an anti-CD34 antibody to mark endothelium in 
the frozen sections. The endothelium (equal to 6,000 ECs) was isolated 
using LCM and subjected to RNA extraction. Half of the isolated RNA was 
used for the quality control of the LCM-captured endothelium. To examine 
the purity of the isolated endothelium and possible contamination by non-
endothelium  tissues,  RT-PCR  was  performed  to  amplify  transcripts  of 
CD34, CD19, CD20, and CD3. To amplify a 213-bp CD19 fragment, a 
sense primer (5-CAGCTGACCTGGTCTCGGGAGT-3) and an antisense 
primer (5-CCCGCTGCCCTCCACATTGACT-3) were used. To am-
plify a 223-bp CD34 fragment, a sense primer (5-GTGGCTGATACC-
GAATTGTGAC-3)  and  an  antisense  primer  (5-CTCCAGGGAGCG-
AATGTGTAAA-3) were used. To amplify a 242-bp human CD20 frag-
ment, a sense primer (5-TACACCTGCCTCATGCTCAG-3) and an an-
tisense  primer  (5-TTCACAAGCCTTCTCACACG-3)  were  used.  To 
amplify a 223-bp CD3 fragment, a sense primer (5-TGAGGGCAAGAGT-
GTGTGAG-3) and an antisense primer (5-TAGTCTGGGTTGGGAA-
CAGG-3) were used. To amplify a 180-bp -actin internal control frag-
ment, a 5 sense primer (5-CTCACGAAACTGGAATAAGC-3) and a 3 
antisense primer (5-AAGCCACACGTACTAAAGGT-3) were used. If 
contamination of nonendothelium tissues was excluded, which was defined 
as no amplification of transcripts of lymphocyte markers (CD19, CD20, or 
CD3), the samples were used for subsequent GeneChip probe arrays. Total 
RNA was extracted, underwent a nonbiased nucleic acid amplification pro-
cedure, and was subsequently subjected to oligonucleotide microarray analy-
sis. A GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) was 
used for the current study. This array comprises 1,300,000 unique oligonu-
cleotide probes covering >47,000 transcripts and variants, which represents 
39,000 of the best-characterized human genes. A probe set consists of 11–20 
probe pairs for detecting each expressed transcript. The analysis software that 
accompanied the microarray (Suite 5; Affymetrix) was used to process the 518 Tim-3+ endothelia assist lymphoma immune evasion | Huang et al.
multiplex TCR PCR experiment was then repeated using purified CD4+ 
and CD8+ cells co-cultured with ADV-TT–infected UVECs.
Cytotoxicity assay. Dendritic cells were infected with ADV-TT at an 
MOI of 250 for 2 h and cultured for another 24 h. TT-loaded dendritic cells 
were harvested and added to a culture plate of autologous T lymphocytes at 
a ratio of 1:20 after 5 d and again 5 d later. The resulting lymphocytes were 
added to UVECs infected with various adenoviral mutants at different E/T 
ratios in triplicate for 4 h. The culture supernatant was determined by a stan-
dard lactate dehydrogenase (LDH) release assay using an LDH cytotoxicity 
assay kit (Biovision Inc.). Specific lysis was determined as follows: percentage 
of specific release = 100 × (experimental release  spontaneous release)/
(maximum release  spontaneous release). For quality control, spontaneous 
release must be <20% of the maximum release in all experiments.
Cytokine bead assay (CBA). To measure cytokine levels, a CBA was 
performed using a CBA immunoassay kit (CBA Human Th1/Th2 Cytokine 
Kits I and II; BD) according to the manufacturer’s instructions. Data were 
acquired using a flow cytometer (FACSCalibur; BD).
Fixation of cells. For fixation experiments, ECs were digested using 0.25% 
trypsin and 1 mM EDTA, seeded onto uncoated 24-well plates, infected 
with various adenoviral mutants at an MOI of 250 for 2 d, and fixed with 2% 
paraformaldehyde for 1 h at 4°C. Thereafter, fixed cells, together with the 
untreated fraction, were washed extensively and mixed with CFSE-labeled 
autologous T lymphocytes for proliferation assays. For fixation of CD4+ and 
CD8+ T cells, the cells were isolated and fixed with 2% paraformaldehyde 
for 1 h at 4°C before co-culturing with ECs for cytokine assays.
Preparation of recombinant protein. An expression plasmid of human 
recombinant  galectin-9  protein  was  constructed  as  described  previously 
(Nobumoto et al., 2008). Chinese hamster ovary (CHO) cells were transfected 
with the plasmid indicated in the figures with Lipofectamine 2000 (Invitro-
gen) transfection reagent. The transfected cells were selected in complete me-
dium containing 1 mg/ml G418 (Invitrogen) and were subsequently cloned 
by limiting dilution. The supernatants of the transfected cells were collected, 
the abundance of galectin-9 was detected by Western blotting, and the super-
natants were then stored at 80°C for future experiments. To produce re-
combinant  Tim-3  protein  labeled  with  red  florescent  protein,  a  cDNA 
sequence encoding the signal peptide and extracellular domain of Tim-3 was 
synthesized by the AuGCT Biotechnology Corporation and inserted into the 
SacI–ApaI site of a pDsRed-Express-1 vector to generate pTim-3–RED. The 
constructed pTim-3–RED was confirmed by DNA sequencing and expected 
to express a fusion protein consisting of the extracellular domain of Tim-3 
with the RED fragment at its C terminus. CHO cells were transfected with 
pTim-3–RED or pDsRed-Express-1. The transfected cells were selected in 
complete medium containing 1 mg/ml G418 and subsequently cloned by 
limiting dilution. Expression of pTim-3–RED or pDsRed-Express-1 was ex-
amined by fluorescence microscopy. The supernatants of the transfected cells 
were collected, the abundance of Tim-3–RED was detected by Western 
blotting, and the supernatants were stored at 80°C for future experiments.
Mouse tumor model studies. All animal protocols were approved by the 
Institutional Animal Care and Use Committee of Tongji Medical College. 
Male and female TA2 mice were obtained from the Animal Experimental 
Center of Tianjin Cancer Institute. An experimental model of transplantable 
B lymphoma in TA2 mice was established. This model was derived from 
spontaneous lymphoma in a TA2 mouse, remained stable past 43 generations 
by successful transplantations in TA2 mice over 4 yr, and developed rapidly 
growing and highly invasive metastases in 100% of mice. Mice were random-
ized when 4–6 wk of age and inoculated with 5 × 105 lymphoma cells into 
the inguinal groove muscle. ECs were isolated and purified from the bone 
marrow of healthy TA2 mice as previously described (Göthert et al., 2004), 
and infected with ADV–Tim-3 (n = 8), Adv-GFP (n = 8), or PBS (n = 8) at 
an MOI of 500. 5 × 104 ECs were injected into the same sites 3, 6, and 9 d 
vectors used in this study were constructed using the AdEasy system (MP 
Biomedicals) according to the manufacturer’s instructions. The ADV-TT 
expression cassette contains an exogenic gene of TT, which is composed of 
parts of fragment C of TT (aa 865–1120 and 1162–1169 of TT), with a 
leader sequence derived from the H chain variable region of the IgM of a 
B cell lymphoma.
Flow  cytometry. A FACScan cytometer and CellQuest software (both 
from BD) were used for data acquisition and analysis. To determine the purity 
of ECs isolated from lymph nodes, the cells were double stained with directly 
conjugated anti-CD31 (FITC; BD) and anti-CD105 (PE; BD). To determine 
the expression of MHC and co-stimulatory molecules, cultured UVECs were 
stained with either directly conjugated anti–MHC class I (FITC; BD), anti–
MHC class II (FITC; BD), anti-CD80 (FITC; BioLegend), or anti-CD58 
(PE; BioLegend). To study the interaction of UVECs with autologous T cells 
and the effects of Tim-3 on this interaction, umbilical vein T lymphocytes were 
stimulated by autologous UVECs infected with different adenoviral mutants. 
The cells were then stained with directly conjugated anti-CD4, anti-CD8, 
anti-CD28, anti-CD25, anti-CD127, or anti–IFN- (BD). To determine the 
influence of various adenoviral mutants on the survival of UVECs, UVECs 
were infected with various adenoviral mutants for 72 h and resuspended in 
binding buffer. 5 µm FITC plus annexin V (BD) and 10 µl propidium iodide 
solution at a concentration of 50 µg/ml in PBS were added, and the cells were 
incubated for 20 min at room temperature in the dark. Stained cells were then 
subjected to flow cytometry analysis.
RT-PCR. To detect isoforms of Tim-3 transcripts, RT-PCR was performed. 
Total RNA was extracted from freshly isolated lymphoma ECs. A 5 sense 
primer (5-CGGAGGTCGGTCAGAATGCCTATC-3) and a 3 antisense 
primer (5-GGGCTCCTCCACTTCATATACGTTC-3) were used to am-
plify Tim-3 transcripts. The expected product for full-length Tim-3 is 749 bp 
and  for  sTim-3  is  541  bp.  A  5  sense  primer  (5-CTCACGAAACTG-
GAATAAGC-3) and a 3 antisense primer (5-AAGCCACACGTACTA-
AAGGT-3) were used to amplify a 180-bp -actin internal control.
Western blotting. Preparation of protein samples and Western blots were 
performed as described previously (Gao et al., 2006).
Cell proliferation assays. Lymphocyte proliferation assays were performed 
as previously described (Coupel et al., 2004). In brief, after erythrocyte lysis, 
3–4 × 107 cells were suspended in 500 µl RPMI 1640, and 4 µl of a solution 
prepared by mixing 50 µl of 5 mM CFSE (Sigma-Aldrich) stock solution and 
450 µl DMSO (AppliChem) was added. The cell solution was then incubated 
for 30 min at 37°C and washed twice with 10 ml PBS (+0.1% BSA) after-
ward. The cells were resuspended in 500 µl of 0.9% NaCl and again counted 
in a counting chamber. Lymphocytes were stimulated with UVECs infected 
with various adenoviral mutants after 3 d and again 3 d later. The staining was 
assayed by FACS analysis, and the proliferation index was processed with 
FlowJo software (Tree Star, Inc.). The proliferation index was defined as the 
sum of the cells in all generations divided by the calculated number of original 
parent cells. This was useful for comparing the quantity of all cell divisions 
among cultures of the same kinds of cells undergoing different treatments.
Biomed-2 multiplex TCR PCR. To assess clonal expansion of T lympho-
cytes in response to ECs infected with ADV-TT, the Biomed-2 multiplex 
TCR PCR technique was used, as described previously (van Dongen et al., 
2003).  In  brief,  multiplex  PCR  was  used,  according  to  a  standardized 
Biomed-2 PCR protocol, to amplify six subfamily genes, including TCR, 
TCR, and TCR, of TCRs from activated lymphocytes. The PCR products 
were run on 1.5% agarose gels or 6% denatured polyacrylamide gels (SILVER 
SEQUENCE Staining Reagents; Promega) for heteroduplex analysis. A spe-
cific PCR band visible in the corresponding position was judged as a positive 
clonal TCR rearrangement (van Dongen et al., 2003). To address which 
subset of T cells was clonally expanded, CD4+ and CD8+ cells were isolated 
by magnetic cell sorting columns (MACS; Miltenyi Biotec). The Biomed-2 JEM VOL. 207, March 15, 2010 
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